Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases

被引：0
作者：
Carsten Nieder
Ellinor Haukland
Adam Pawinski
Astrid Dalhaug
机构：
[1] Department of Oncology and Palliative Medicine,Institute of Clinical Medicine
[2] Nordland Hospital,undefined
[3] Faculty of Health Sciences,undefined
[4] University of Tromsø,undefined
来源：
BMC Urology | / 10卷
关键词：
Prostate Cancer; Bone Metastasis; Zoledronic Acid; Pathologic Facture; Taxotere;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 120 条
  • [11] Smith MR(2008)The cost of treating skeletal-related events in patients with prostate cancer Am J Manag Care 14 317-322
  • [12] Cook RJ(2008)Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy J Clin Oncol 26 4426-4434
  • [13] Coleman R(2005)Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease Br J Cancer 93 633-638
  • [14] Brown J(2007)Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases Clin Genitourin Cancer 5 390-396
  • [15] Lipton A(2002)Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival Cancer 95 1028-1036
  • [16] Major P(2001)A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma Cancer 92 303-310
  • [17] Hei Yj(2009)Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease Prostate Cancer Prostatic Dis 12 94-99
  • [18] Saad F(2009)Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid Prostate 69 624-632
  • [19] Aass N(undefined)undefined undefined undefined undefined-undefined
  • [20] Fosså SD(undefined)undefined undefined undefined undefined-undefined
12345678910